Independent Recognition Reinforces Auragens' Position as a Global Leader in Regenerative Medicine

LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--Auragens today announced it has been named Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, becoming the first organization to receive the publication's highest distinction for two consecutive years.

Unlike traditional treatment providers, Auragens operates as a vertically integrated regenerative medicine enterprise designed to accelerate innovation while maintaining complete oversight across every stage of the patient and biologics lifecycle.

Share

While the award recognizes excellence in patient care, it also reflects a broader transformation taking place within regenerative medicine—one in which scientific rigor, manufacturing quality, regulatory oversight, and integrated clinical delivery are becoming the defining characteristics of industry leadership.

For Auragens, recognition validates a strategic vision that began years ago.

Rather than building another regenerative medicine clinic, the company set out to create one of the world's first fully integrated regenerative medicine platforms—bringing together advanced biologics manufacturing, physician-led clinical care, translational research, quality systems, scientific publication, and global collaboration under a single organizational framework.

As regenerative medicine continues its transition from an emerging field to a mature scientific discipline, Auragens believes long-term leadership will increasingly be determined by measurable capabilities rather than marketing claims.

"Our mission has never been to compete within the existing regenerative medicine landscape," said Dr. Dan Briggs, Chief Executive Officer and President of Auragens, "our mission has been to help define what that landscape should become."

Building an Integrated Regenerative Medicine Enterprise

Unlike traditional treatment providers, Auragens operates as a vertically integrated regenerative medicine enterprise designed to accelerate innovation while maintaining complete oversight across every stage of the patient and biologics lifecycle.

Today, the Auragens platform includes:

Scientific Leadership

Auragens investigators have authored more than 20 peer-reviewed scientific publications, five bestselling books, and have presented original research and clinical findings throughout North America, South America, and Europe, including invited presentations at the prestigious NASA ASCEND Conference.

The company actively collaborates with internationally respected institutions and organizations including numerous universities, heads-of-state, government contractors, and global health organizations, helping advance regenerative medicine through scientific discovery, translational research, and real-world clinical application.

Manufacturing Excellence

At the core of the Auragens platform is an advanced on-site cellular manufacturing laboratory that has produced more than 500 billion stem cells under comprehensive quality systems.

Auragens also operates an AABB-accredited Cellular Therapy Laboratory, representing one of the highest internationally recognized standards for quality management in cellular therapy operations.

The company's vertically integrated model provides complete oversight from donor screening and biologics manufacturing through physician-directed clinical administration—an infrastructure rarely found within a single regenerative medicine organization.

Clinical Excellence

Auragens has welcomed patients from more than 40 countries across six continents, serving individuals seeking advanced regenerative therapies in an environment built around scientific integrity, personalized care, and measurable outcomes.

The organization has also become a trusted destination for elite athletic performance and recovery, caring for professional athletes from the NFL, NBA, MLB, NHL, PGA Tour, Olympic competition, and international tennis.

Innovation Platform

Auragens continues expanding its capabilities through strategic investments in translational medicine, physician education, biologics manufacturing, and new therapeutic applications.

The recent launch of the company's dedicated Orthobiologics Division represents another milestone in its commitment to advancing musculoskeletal medicine and sports performance through evidence-based regenerative therapies.

Independent Recognition Reflecting Sustained Excellence

The latest honor joins an expanding portfolio of international recognitions awarded to Auragens and its leadership, including:

• Stem Cell Treatment Center of the Year (2025 & 2026)
• Regenerative Medicine Solutions Provider of the Year (2026)
• Most Innovative Company (2026)
• World's Top 100 Innovators (2026)
• Business of the Year (2025)
• Healthcare CEO of the Year (2023 & 2026)
• Medical Researcher of the Year (2025)
• Visionary Healthcare Leader of the Year (2026)
• EY Entrepreneur of the Year (2026)

Collectively, these recognitions reflect an organization whose influence extends beyond patient care into scientific research, cellular manufacturing, healthcare innovation, and global leadership within regenerative medicine.

Looking Forward

The regenerative medicine industry is entering a defining decade.

Scientific validation, manufacturing excellence, regulatory rigor, published evidence, and integrated delivery systems will increasingly distinguish enduring leaders from conventional providers.

Auragens believes this evolution will reshape not only how regenerative medicine is practiced, but how it is evaluated by patients, physicians, researchers, healthcare systems, governments, and strategic partners around the world.

As the company continues expanding its international collaborations, scientific research, manufacturing capabilities, and clinical programs, it remains committed to establishing the global benchmark for regenerative medicine through measurable excellence, transparency, and innovation.

"The future of regenerative medicine will not be defined by promises," said Briggs, “it will be defined by proof."

About Auragens – Auragens is the market leader in the field of stem cell treatments, research, and development. As a complete regenerative medicine platform they operate their own laboratory onsite and are ISO certified, AABB Accredited and follow all cGMP guidelines and FDA related regulations for safety. Treatments are provided at their private state-of-the-art facility in Panama City, Panama and spans the entire 48^th floor of a Class A office building in the Beverly Hills of Panama City, known as Punta Pacifica. All science and medicine is overseen by a team of doctors hailing from universities such as Johns Hopkins, Stanford and Notre Dame among others. Published in numerous journals, recipient of Medical Researcher of the Year and Business of the Year, Auragens is leading in cutting edge Regenerative Medicine with a goal of making their treatments a Standard of Care and available to all in need.

.